Biomind Labs Inc. (BMNDF)

OTCMKTS · Delayed Price · Currency is USD
0.105
0.00 (0.00%)
Apr 28, 2026, 9:30 AM EST
-85.01%
Market Cap 8.14M
Revenue (ttm) n/a
Net Income (ttm) -850.41K
Shares Out 77.57M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 3,244
Open 0.105
Previous Close 0.105
Day's Range 0.105 - 0.105
52-Week Range 0.011 - 0.131
Beta -0.14
RSI 46.67
Earnings Date May 14, 2026

About Biomind Labs

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Alejandro Antalich
Country Canada
Stock Exchange OTCMKTS
Ticker Symbol BMNDF
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.